Merck & Co returns antifungal to Anacor amid reprioritisation
This article was originally published in Scrip
Executive Summary
Merck & Co has returned full global development and commercialisation rights for AN2690, a topical treatment for onychomycosis, to Anacor Pharmaceuticals.